Miriam Bazan-Peregrino

6PUBLICATIONS
38CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 08, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy.

|Mar 26, 2022
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.

Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín

|Feb 12, 2022
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.

Miriam Bazan-Peregrino, Rocio Garcia-Carbonero, Berta Laquente

|Feb 02, 2021
Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.

Martí Farrera-Sal, Laura Moya-Borrego, Miriam Bazan-Peregrino

|Jul 26, 2020
Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral Fitness.

Martí Farrera-Sal, Jana de Sostoa, Estela Nuñez-Manchón

|Jan 25, 2019
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.

Guillem Pascual-Pasto, Miriam Bazan-Peregrino, Nagore G Olaciregui

Pageof 1

Frequent Collaborators

3 joint publications

Marti Farrera-Sal

3 joint publications

Rafael Moreno

3 joint publications

Ramon Alemany

1 joint publications

Guillem Pascual-Pasto